Mirae Asset Global Investments Co. Ltd. Sells 10,260 Shares of Repligen Corporation $RGEN

Mirae Asset Global Investments Co. Ltd. lessened its position in Repligen Corporation (NASDAQ:RGEN) by 34.8% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 19,262 shares of the biotechnology company’s stock after selling 10,260 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in Repligen were worth $2,575,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of RGEN. Hantz Financial Services Inc. boosted its holdings in shares of Repligen by 2,663.6% during the second quarter. Hantz Financial Services Inc. now owns 304 shares of the biotechnology company’s stock worth $38,000 after purchasing an additional 293 shares during the period. CWM LLC raised its position in Repligen by 67.2% during the 3rd quarter. CWM LLC now owns 336 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 135 shares during the last quarter. Center for Financial Planning Inc. lifted its holdings in Repligen by 34.2% in the 2nd quarter. Center for Financial Planning Inc. now owns 494 shares of the biotechnology company’s stock worth $61,000 after buying an additional 126 shares during the period. Trust Co. of Vermont bought a new stake in shares of Repligen in the 3rd quarter worth approximately $67,000. Finally, Wilmington Savings Fund Society FSB increased its stake in shares of Repligen by 2,750.0% during the third quarter. Wilmington Savings Fund Society FSB now owns 513 shares of the biotechnology company’s stock valued at $69,000 after buying an additional 495 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Analyst Ratings Changes

Several analysts recently weighed in on the stock. Barclays lifted their price target on shares of Repligen from $175.00 to $200.00 and gave the company an “overweight” rating in a report on Monday, December 15th. Jefferies Financial Group set a $160.00 target price on shares of Repligen and gave the company a “hold” rating in a research note on Tuesday, October 28th. UBS Group increased their price target on shares of Repligen from $190.00 to $200.00 and gave the stock a “buy” rating in a research note on Friday, January 16th. Wells Fargo & Company lifted their price objective on Repligen from $175.00 to $190.00 and gave the company an “overweight” rating in a research report on Monday, December 15th. Finally, Evercore ISI upped their target price on Repligen from $155.00 to $175.00 and gave the stock an “outperform” rating in a report on Tuesday, October 7th. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $179.62.

Insiders Place Their Bets

In other news, Director Anthony Hunt sold 20,000 shares of Repligen stock in a transaction dated Thursday, November 13th. The stock was sold at an average price of $154.61, for a total value of $3,092,200.00. Following the completion of the transaction, the director owned 80,743 shares of the company’s stock, valued at $12,483,675.23. The trade was a 19.85% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, COO James Bylund sold 2,191 shares of the company’s stock in a transaction dated Tuesday, November 18th. The stock was sold at an average price of $151.21, for a total transaction of $331,301.11. Following the completion of the transaction, the chief operating officer owned 21,520 shares in the company, valued at approximately $3,254,039.20. The trade was a 9.24% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 49,657 shares of company stock valued at $7,721,077. 1.20% of the stock is currently owned by corporate insiders.

Repligen Price Performance

Shares of RGEN opened at $151.12 on Tuesday. The firm’s 50-day simple moving average is $164.05 and its two-hundred day simple moving average is $144.43. Repligen Corporation has a fifty-two week low of $102.96 and a fifty-two week high of $175.77. The stock has a market cap of $8.51 billion, a PE ratio of 7,559.78, a price-to-earnings-growth ratio of 2.71 and a beta of 1.13. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.14 and a current ratio of 8.36.

Repligen Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.